Clinical trial
A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV)…
NCT00051051 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00051051 |
|---|---|
| Title | A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer |
| Official title | A Phase II, Randomized, Open-Label Study of Single Agent CI-1033 in Patients With Metastatic Breast Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | CI-1033 |
| Enrollment | 168 |
| Start date | Dec 1, 2002 |
| Completion | May 1, 2005 |
| First posted | Jan 3, 2003 |
| Last update posted | May 4, 2007 |
| Countries | Belgium, Canada, France, Ireland, Italy, Spain, Sweden, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: